ZTS Q2 2026 Earnings Analysis
Q2 revenue declined 1% organically to $2.5B amid U.S. Companion Animal pressures, prompting full-year guidance reduction to $9.12-$9.32B revenue and $2.57-$2.62B adjusted net income.
Key Metrics
Points clés
- U.S. Companion Animal pressured by clinic declines and competition; using gross-to-net actions to defend share.
- Livestock and Diagnostics deliver strong growth; pipeline includes 12 potential blockbusters over next years.
- Full-year guidance lowered to $9.12-$9.32B revenue, $2.57-$2.62B adj. net income due to headwinds.
Écouter sur
Disponible en
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown, where we take the numbers and the noise from corporate earnings calls and turn them into something you can actually digest. I'm Alex.
And I'm Jordan. Today we're diving into Zoetis, ticker ZTS, the animal health giant. Q2 2026 results, and Alex, this one's a bit of a bumpy ride.
It really is. But before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Good to have that out front. So let's set the scene. Zoetis reported second quarter revenue of $2.5 billion — flat on a reported basis, actually down 1% organically. Adjusted net income came in at $781 million, down 2% organically. And here's the headline: they cut full-year guidance.
Yeah, this wasn't a small tweak either. New revenue guidance is $9.12 to $9.32 billion, which works out to a decline of 3% to 1% for the year. Adjusted net income guidance dropped to a range implying a decline of 9% to 5%. That's a meaningful reset.
So what happened? Basically, the U.S. Companion Animal business — think dogs and cats, not cattle and chickens — got hit hard. Revenue there was down 11% in the U.S. Fewer vet visits, pet owners being more price-conscious, and a lot more competitors piling into categories Zoetis basically invented, like dermatology treatments.
Right, and that's the key tension here. Their blockbuster drug Apoquel and the whole Key Dermatology franchise — U.S. dermatology revenue was down 18% in the quarter. New competitors are using aggressive discounting and rebates to steal share, and it's not growing the overall market, it's just splitting up a shrinking pie.
Even so, Zoetis still holds about 86% in-clinic share in U.S. dermatology, even after losing 10 points year-over-year. So they're still dominant, just under real pressure for the first time in a while.
And parasiticides — flea, tick, heartworm meds like Simparica — were basically flat globally, with the U.S. side down 6%. Management said it's less about a specific competitor and more about a broader pullback in vet visits.
But here's the plot twist — it's not all bad news. Livestock had a phenomenal quarter, up 11% globally, and 23% in the U.S., partly boosted by demand for cattle parasiticides tied to that New World screwworm outbreak. And Diagnostics grew 12%, driven by point-of-care testing demand.
So basically, the pet side is struggling, but the farm animal side and the diagnostics side are picking up a lot of the slack.
Exactly — that diversification is doing real work for them right now.
Let's talk strategy, because CEO Kristin Peck was pretty clear about their playbook. Instead of cutting list prices — which she called a "permanent structural change" — they're doing what's called gross-to-net investment. Basically targeted rebates, promotions, and bundling deals to protect market share without blowing up their pricing structure long-term.
It's a defend-the-fort strategy. Protect volume and share now, keep the sticker price intact, and hope the competitive intensity eases once the market sorts itself out. CFO Wetteny Joseph said full-year price realization could land anywhere from flat to down 2%, depending on how aggressive they need to get.
There's also a leadership shakeup worth mentioning. Wetteny Joseph, the CFO, is stepping down after five years — a new hire, Jay Saccaro, is coming in not just as CFO but in a newly created combined CFO and Chief Operating Officer role, overseeing manufacturing and supply chain too. That's a pretty significant restructuring of the C-suite, aimed at speeding up decision-making.
And Abhay Nayak, who used to run their diagnostics division, was just promoted to head U.S. commercial operations — so there's clearly a sense of urgency here to get fresh eyes and faster execution on the ground in the U.S., where the pain is concentrated.
One thing that stood out to me in the Q&A was an analyst basically asking Kristin Peck point blank: "Do you actually have the better product anymore?" Apoquel's ten years old at this point.
And her answer was interesting — she didn't dodge it. She said, essentially, yes, we still believe we have superior safety and efficacy, but in a market where pet owners are stretched financially, sometimes "good enough" and cheaper wins the moment. So their job is proving the value, not just assuming loyalty.
There was also a good exchange on the pipeline. Despite all this near-term noise, management kept emphasizing they have 12 potential blockbuster products in development, including a long-acting version of Cytopoint expected to get FDA approval later this year, plus expansion of newer pain treatments like Librela's successor, Lenvia, and the feline pain drug Portela rolling out internationally.
So the long-term innovation story isn't going away — it's just that the next year or so is going to be about defense, not offense.
So what does this mean for investors? The big picture: this is a company facing a genuine competitive inflection point in its most profitable business line, companion animal health, at the same time consumer spending on pets is getting squeezed. Management's response is targeted pricing discipline rather than panic discounting, cost cuts — SG&A was down 4% — and leaning on livestock and diagnostics as ballast.
The stock buyback tells you something too — they repurchased over $550 million in shares this quarter, above their historical average, which signals management thinks the selloff has been overdone relative to the long-term fundamentals.
The open question is timing — how long does this competitive pressure last? Kristin Peck herself said she couldn't say if it's six, twelve, or eighteen months before things stabilize. That uncertainty is really the crux of the story right now.
Before we wrap up — everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Well said. So bottom line: Zoetis is navigating real near-term headwinds in companion animal care, leaning on livestock and diagnostics strength, and betting that disciplined defense now sets up better footing heading into 2027.
A quarter of transition, for sure — new CFO, new commercial leadership, and a market that's testing whether their pipeline and brand loyalty can outlast the current wave of competition.
That's it for this episode of Beta Finch. Thanks for listening, and we'll catch you next time we break down the numbers.
See you then.